Research programme: incrementally modified drugs - Sam Chun Dang Pharm
Latest Information Update: 18 Jul 2016
At a glance
- Originator Sam Chun Dang Pharm
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Diabetes mellitus; Hyperlipidaemia
Most Recent Events
- 18 Jul 2016 Early research in Hyperlipidaemia in South Korea (unspecified route)
- 18 Jul 2016 Early research in Diabetes mellitus in South Korea (unspecified route)